SKYRIZI

This brand name is authorized in Austria, Australia, Brazil, Canada, Ecuador, Estonia, Spain, Finland, France, Hong Kong, Croatia, Ireland, Israel, Italy, Japan, Lithuania, Netherlands, New Zealand, Poland, Romania, Turkey, United Kingdom, United States

Active ingredients

The drug SKYRIZI contains one active pharmaceutical ingredient (API):

1 Risankizumab UNII 90ZX3Q3FR7 - RISANKIZUMAB

Risankizumab is a humanised immunoglobulin G1 (IgG1) monoclonal antibody that selectively binds with high affinity to the p19 subunit of human interleukin 23 (IL-23) cytokine and inhibits IL-23-dependent cell signalling and release of proinflammatory cytokines. Risankizumab is indicated for the treatment of moderate to severe plaque psoriasis. Read about Risankizumab

Medication package inserts

Below package inserts are available for further reading:

Title	Information Source	Document Type
SKYRIZI 75 mg / 150 mg Solution for injection	European Medicines Agency (EU)	MPI, EU: SmPC
SKYRIZI 90 mg / 180 mg / 360 mg Solution for injection	European Medicines Agency (EU)	MPI, EU: SmPC
SKYRIZI 600 mg Concentrate for solution for infusion	European Medicines Agency (EU)	MPI, EU: SmPC

Medicine classification

This drug has been classified in the anatomical therapeutic chemical (ATC) classification system as follows:

ATC code	Group title	Classification
L04AC18		L Antineoplastic and immunomodulating agents → L04 Immunosuppressants → L04A Immunosuppressants → L04AC Interleukin inhibitors
Discover more medicines within L04AC18

Authorization and marketing

This drug has been assigned below unique identifiers within the countries it is being marketed:

Country	Identification scheme	Identifier(s)
Country: AU	Pharmaceutical Benefits Scheme	Identifier(s): 11827L, 11858D
Country: BR	Câmara de Regulação do Mercado de Medicamentos	Identifier(s): 543719110004107
Country: CA	Health Products and Food Branch	Identifier(s): 02487454
Country: EC	Agencia Nacional de Regulación, Control y Vigilancia Sanitaria	Identifier(s): 174-MBE-0121, 235-MBE-0822
Country: EE	Ravimiamet	Identifier(s): 1794102, 1848416, 1848427, 1848438
Country: ES	Centro de información online de medicamentos de la AEMPS	Identifier(s): 1191361001
Country: FI	Lääkealan turvallisuus- ja kehittämiskeskus	Identifier(s): 055240, 409325, 557887
Country: FR	Base de données publique des médicaments	Identifier(s): 67060271
Country: GB	Medicines & Healthcare Products Regulatory Agency	Identifier(s): 371219, 397916, 397922
Country: HK	Department of Health Drug Office	Identifier(s): 66488
Country: IL	מִשְׂרַד הַבְּרִיאוּת	Identifier(s): 9258, 9259, 9314, 9315
Country: IT	Agenzia del Farmaco	Identifier(s): 047821018, 047821020, 047821032, 047821044, 047821057
Country: JP	医薬品医療機器総合機構	Identifier(s): 3999450A1025, 3999450G1028, 3999450G2024, 3999450G3020, 3999450G4027
Country: LT	Valstybinė vaistų kontrolės tarnyba	Identifier(s): 1087673, 1092291, 1092292
Country: NL	Z-Index G-Standaard, PRK	Identifier(s): 197629
Country: NZ	Medicines and Medical Devices Safety Authority	Identifier(s): 20126, 21860, 21949
Country: PL	Rejestru Produktów Leczniczych	Identifier(s): 100417814, 100461473
Country: RO	Agenția Națională a Medicamentului și a Dispozitivelor Medicale	Identifier(s): W66053001, W67699001, W67700001, W69348001, W69349001
Country: TR	İlaç ve Tıbbi Cihaz Kurumu	Identifier(s): 8680656080520, 8680656080599, 8680656080605
Country: US	FDA, National Drug Code	Identifier(s): 0074-1050, 0074-1065, 0074-1066, 0074-1069, 0074-1070, 0074-2042, 0074-2100, 0074-5015, 0074-7032, 0074-7034, 0074-7036, 0074-7040, 0074-7042